1.

Bayes RT. An essay toward solving a problem in the doctrine of chances. Phil Trans Royal Soc London 1763; 53: 370–418

CrossRef2.

Efron B. Controversies in the foundation of statistics. Am Math Month 1978; 85: 231–246

CrossRef3.

Edwards A. A history of likelihood. Internat Stat Rev 1974; 42: 9–15

CrossRef4.

Kennedy P. A guide to econometrics. 5th ed. Cambridge (MA): MIT Press, 2003

5.

Spiegelhalter DJ, Myles JP, Jones DR, et al. An introduction to Bayesian methods in health technology assessment. BMJ 1999; 319: 508–512

PubMedCrossRef6.

Speigelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. West Sussex (UK): John Wiley & Sons, 2004

7.

Lilford RJ, Braunholtz D. Who’s afraid of Thomas Bayes? J Epidem Community Health 2000; 54: 731–739

CrossRef8.

Shih YCT. Bayesian approach in pharmacoeconomics: relevance to decision-makers. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3: 237–250

CrossRef9.

Dunson DB. Practical advantages of Bayesian analysis of epidemiologic data. Am J Epidem 2001; 153: 1222–1226

CrossRef10.

Spiegelhalter DJ. Incorporating Bayesian ideas into health-care evaluation. Stat Sci 2004; 19: 156–174

CrossRef11.

Stangl DK, Berry DA. Bayesian statistics in medicine: where are we and where should we be going? Sankhya: Indian J Stat 1998; 60: 176–195

12.

Lilford RJ. The statistical basis of public policy: a paradigm shift is overdue. BMJ 1996; 313: 603–607

PubMedCrossRef13.

Wilson G. Tides of change: is Bayesianism the new paradigm in statistics? J Stat Plan Inference 2003; 113: 371–374

CrossRef14.

Bayarri MJ, Berger JO. The interplay of Bayesian and frequentist analysis. Stat Sci 2004; 19: 58–80

CrossRef15.

Wilkinson GN. On resolving the controversy in statistical inference [with discussion]. J Royal Stat Soc Series B (Methodology) 1977; 39: 119–171

16.

Goodman SN. Toward evidence-based medical statistics: 1. The p-value fallacy. Ann Intern Med 1999; 130: 995–1004

PubMed17.

Emerson SS, Kittelson JM, Gillen DL. Bayesian evaluation of group sequential clinical trial designs. University of Washington Biostatistics Working Papers Series: paper 242 [online]. Available from URL: http://www.bepress.com/uwbiostat/paper242 [Accessed 2005 Jul 4]

18.

Bland JM, Altman DG. Bayesians and frequentists. BMJ 1998; 317: 1151

PubMedCrossRef19.

Freund JE. Mathematical statistics. 2nd ed. Englewood Cliffs (NJ): Prentice Hall, 1971

20.

Grinstead CM, Snell JL. Introduction to probability. 2nd ed. Washington, DC: American Mathematical Society, 1997

21.

Dorfman JH. Bayesian economics through numerical methods: a guide to decision-making with prior information. New York (NY): Springer, 1997

22.

Jeffreys H. Theory of probability. 3rd ed. Oxford (UK): Clarendon, 1961

23.

O’Hagan A, Luce B. A primer on Bayesian analysis in health economics and outcomes research. Sheffield (UK): Centre for Bayesian Statistics in Health Economics, 2003

24.

Skrepnek GH. Regression methods in the empirical analysis of health care data. J Manag Care Pharm 2005; 11: 240–251

PubMed25.

Casella G, Berger RL. Statistical inference. 2nd ed. Belmont (CA): Duxbury, 2001

26.

Woolridge JM. Introductory econometrics: a modern approach. 2nd ed. Mason (OH): Thomson Southwestern, 2003

27.

Neyman J. Frequentist probability and frequentist statistics. Synthese 1977; 36: 97–131

CrossRef28.

Skrepnek GH. Cost-effectiveness analysis. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principles of pharmacoeconomics. 3rd ed. Cincinnati (OH): W Harvey Whitney, 2005

29.

Sterne JAC, Smith GD. Sifting the evidence: what’s wrong with significance tests. BMJ 2001; 322: 226–231

PubMedCrossRef30.

Berger JO, Sellke T. Testing a point null hypothesis: the irreconcilability of p-values and evidence (with discussion). J Am Stat Assoc 1987; 82: 112–139

31.

Cowles M, Davis C. On the origins of the.05 level of statistical significance. Am Psychol 1982; 37: 553–558

CrossRef32.

Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65–70

33.

Rothman KJ. No adjustments needed for multiple comparisons. Epidem 1990; 1: 43–46

CrossRef34.

Theil H, Goldberger AS. On pure and mixed statistical estimation in economics. Internat Econ Rev 1961; 2: 65–78

CrossRef35.

Goodman SN. Toward evidence-based medical statistics: 2. The Bayes Factor. Ann Intern Med 1999; 130: 1005–1013

PubMed36.

Good I. Probability and the weighing of evidence. New York (NY): Charles Griffin, 1950

37.

Berry DA. A case for Bayesianism in clinical trials. Stat Med 1993; 12: 1377–1393

PubMedCrossRef38.

DeGroot MH. Optimal statistical decisions. New York (NY): McGraw-Hill, 1970

39.

Cornfield J. Recent methodological contributions to clinical trials. Am J Epidem 1976; 104: 408–421

40.

Bala MV, Mauskopf J. Estimating the Bayesian loss function: a conjoint analysis approach. Intern J Technol Assess Health Care 2001; 17: 27–37

CrossRef41.

Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999; 8: 257–261

PubMedCrossRef42.

Luce BR, Claxton K. Redefining the analytic approach to pharmacoeconomics. Health Econ 1999; 8: 187–189

PubMedCrossRef43.

Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006; 24: 1–19

PubMedCrossRef44.

Qin D. Bayesian econometrics: the first twenty years. Econ Theory 1996; 12: 500–516

CrossRef45.

Geman S, Geman D. Stochastic relaxation, Gibbs distributions, and Bayesian restoration of images. IEEE Trans Pattern Anal Mach Intell 1984; 6: 721–741

PubMedCrossRef46.

Brooks SP. Markov Chain Monte Carlo method and its application. Statistician 1998; 47: 69–100

CrossRef47.

Andrieu C, Doucet A, Robert CP. Computational advances for and from Bayesian analysis. Stat Sci 2004; 19: 118–127

CrossRef48.

Winkler RL. Why Bayesian analysis hasn’t caught on in health-care decision making. Internat J Tech Assess Health Care 2001; 17: 56–66

CrossRef49.

Gill CJ, Sabin L, Schmid CH. Why clinicians are natural Bayesians. BMJ 2005; 330: 1080–1083

PubMedCrossRef50.

Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982; 71: 1344–1348

PubMedCrossRef51.

Ashby D, Smith AFM. Evidence-based medicine as Bayesian decision-making. Stat Med 2000; 19: 3291–3305

PubMedCrossRef52.

Bernardo JM, Smith AFM. Bayesian theory. New York (NY): Wiley, 1994

CrossRef53.

The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–682

CrossRef54.

Brophy JM, Joseph L. Placing trials in context using Bayesian analysis. JAMA 1995; 273: 871–875

PubMedCrossRef55.

Troiani JS, Carlin BP. Comparison of Bayesian, classical, and heuristic approaches in identifying acute disease events in lung transplant recipients. Stat Med 2004; 23: 803–824

PubMedCrossRef56.

Delaney BC, Holder RL, Allan TF, et al. A comparison of Bayesian and maximum likelihood methods to determine the performance of a point of care test for Heliobacter pylori in the office setting. Med Decis Making 2003; 23: 21–30

PubMedCrossRef57.

Bloom BS, de Pouvourville N, Libert S. Classic or Bayesian research design and analysis: does it make a difference? Intern J Technol Assess Health Care 2002; 18: 120–126

58.

Spiegelhalter D, Myles J, Jones D, et al. Bayesian methods in health technology assessment: a review. Health Technol Assess 2000; 4: 1–130

PubMed59.

Kadane JB. Prime time for Bayes. Control Clin Trial 1995; 16: 313–318

CrossRef60.

Fisher LD. Comments on Bayesian and frequentist analysis and interpretation of clinical trials. Control Clin Trial 1996; 17: 423–434

CrossRef61.

Urbach P. The value of randomization and control in clinical trials. Stat Med 1993; 12: 1421–1431

PubMedCrossRef62.

Papineau D. The virtues of randomization. Brit J Phil Sci 1994; 455: 437–450

CrossRef63.

Berry DA. Bayesian statistics and the efficiency and ethics of clinical trials. Stat Sci 2004; 19: 175–187

CrossRef64.

Breslow N. Biostatistics and Bayes. Stat Sci 1990; 5: 269–284

CrossRef65.

Pocock S. The combination of randomized and historical controls in clinical trials. J Chron Dis 1976; 29: 175–188

PubMedCrossRef66.

International Conference on Harmonization E9 Expert Working Group. Statistical principles for clinical trials: ICH harmonized tripartite guideline. Stat Med 1999; 18: 1905–1942

67.

Senn S. Consensus and controversy in pharmaceutical statistics (with discussion). Statistician 2000; 49: 135–176

CrossRef68.

Campbell G. A regulatory perspective for Bayesian clinical trials. Washington, DC: US FDA, 1999

69.

Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis: an illustration and application to blood pressure control in type 2 diabetes. Internat J Technol Assess Health Care 2001; 17: 69–82

CrossRef70.

Fryback DC, Chinnis JOP, Ulvila JW. Bayesian cost-effectiveness analysis: an example using the GUSTO trial. Internat J Technol Assess Health Care 2001; 17: 83–97

CrossRef71.

Heitjan DF, Moskowitz AJ, Whang W. Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ 1999; 8: 191–201

PubMedCrossRef72.

O’Hagan A, Stevens JW, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 2000; 17: 339–349

PubMedCrossRef73.

O’Hagan A, Stevens JW, Montmartin J. Bayesian cost-effectiveness analysis from clinical trial data. Stat Med 2001; 20: 733–753

PubMedCrossRef74.

O’Hagan A, Stevens JW. A framework for cost-effectiveness analysis from clinical trial data. Health Econ 2001; 10: 303–305

PubMedCrossRef75.

O’Hagan A, Stevens JW. Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of healthcare technologies. Stat Meth Med Res 2002; 11: 469–490

CrossRef76.

van Hout BA, Al MJ, Gordon GS, et al. Costs, effects, and C/E ratios alongside a clinical trial. Health Econ 1994; 3: 309–319

PubMedCrossRef77.

Stinnett AA, Mullahy J. A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18: 68s–80s

CrossRef78.

Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9: 623–630

PubMedCrossRef79.

Berger J, Phillipe A, Robert C. Estimation of quadratic functions: noninformative priors for non-centrality parameters. Statist Sinica 1998; 8: 359–376

80.

Berger J. Statistical decision theory and Bayesian analysis. 2nd ed. New York (NY): Springer, 1985

81.

Eaton ML. Group invariance applications in statistics. Hayward (CA): IMS, 1989

82.

Robert CP. The Bayesian choice. 2nd ed. New York (NY): Springer, 2001

83.

Chambers ML. A simple problem with strikingly different frequentist and Bayesian solutions. J Royal Stat Soc Series B (Methodological) 1970; 32: 278–282

84.

Bartholomew DJ. A comparison of some Bayesian and frequentist inferences. Biometrika 1965; 52: 19–35

85.

Bartholomew DJ. A comparison of frequentist and Bayesian approaches to inference with prior knowledge: foundations of statistical inference (Proc Sympos, Univ Waterloo, Waterloo, Ont, 1970). Toronto (ON): Holt, Rinehart, and Winston, 1970: 34

86.

Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327–340

PubMedCrossRef87.

Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness analyses. Stat Med 2003; 22: 3687–3709

PubMedCrossRef88.

Cooper NJ, Abrams KR, Sutton AJ, et al. Use of Bayesian methods for Markov modeling in cost-effectiveness analysis: an application to taxane use in advanced breast cancer [technical report, 02-02]. Leicester (UK): University of Leicester, 2002

89.

Sendi PP, Craig BA, Meier G, et al. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. J Antimicrob Chemo 1999; 44: 811–817

CrossRef90.

Matchar DB, Samsa GP, Matthews JR, et al. The stroke prevention policy model: linking evidence and clinical decisions. Ann Intern Med 1997; 127: 704–711

PubMed91.

Al MJ, van Hout BA. A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty. Health Econ 2000; 9: 599–609

PubMedCrossRef92.

Samsa GP, Reutter RA, Parmigiani G, et al. Performing cost-effectiveness analysis by integrating randomised trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. Clin Epidem 1999; 52: 259–271

CrossRef93.

Heitjan DF, Li H. Bayesian estimation of cost-effectiveness: an importance-sampling approach. Health Econ 2004; 13: 191–198

PubMedCrossRef94.

Craig BA, Fryback DG, Klein R, et al. A Bayesian approach to modeling the natural history of a chronic condition from observations with intervention. Stat Med 1999; 18: 1355–1371

PubMedCrossRef95.

Howard RA. Information value theory. IEEE Trans System Sci Cybernetics 1966; SCC2: 22–26

CrossRef96.

Howard RA. Value of information lotteries. IEEE Trans System Sci Cybernetics 1967; SCC3: 24–60

97.

Claxton K, Neumann PJ, Araki S, et al. Bayesian value-of-information analysis. Internat J Technol Assess Health Care 2001; 17: 38–55

CrossRef98.

Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996; 5: 513–524

PubMedCrossRef99.

Claxton K. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ 1999; 8: 269–274

PubMedCrossRef100.

Neumann PJ, Claxton K, Weinstein MC. The FDA’s regulation of health economic information. Health Affairs 2000; 19: 129–137

PubMedCrossRef101.

Claxton K, Schulper M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002; 360: 711–715

PubMedCrossRef102.

Fenwick E, Claxton K, Schulper M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779–787

PubMedCrossRef103.

Felli JC, Hazen GB. A Bayesian approach to sensitivity analyses. Health Econ 1999; 8: 263–268

PubMedCrossRef104.

Parmigiani G. Modeling in medical decision making: a Bayesian approach. Hoboken (NJ): John Wiley & Sons, 2002

105.

Cooper NJ, Sutton AJ, Abrams KR, et al. Comprehensive decision analytic modeling in economic evaluation: a Bayesian approach. Health Economics 2004; 13: 203–226

PubMedCrossRef106.

Harrell F, Shih YCT. Using full probability models to compute probabilities of actual interest to decision makers. Internat J Technol Assess Health Care 2001; 17: 17–26

CrossRef107.

Stangl DK. Bridging the gap between statistical analysis and decision making in public health research. Stat Med 2005; 24: 503–511

PubMedCrossRef108.

Eddy DM, Hasselblad V, Schachter RD. Meta-analysis by the confidence profile method: the statistical synthesis of evidence. Boston (MA): Academic Press, 1992

109.

Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479–500

PubMedCrossRef110.

Vanness DJ, Kim WR. Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation. Health Econ 2002; 11: 551–566

PubMedCrossRef111.

Brennan P. Statistical basis of public policy: epidemiology does not need Bayesian inference [letter]. BMJ 1997; 314: 72

PubMedCrossRef112.

Kass RE, Greenhouse JB. A Bayesian perspective: comment on’ Investigating therapies of potentially great benefit: ECMO’ by JH Ware. Statist Sci 1989; 4: 310–317

CrossRef113.

Lindley DV. Theory and practice of Bayesian statistics. Statistician 1983; 32: 1–11

CrossRef114.

Dawid AP, Stone M, Zidek JV. Marginalization paradoxes in Bayesian and structural inference (with discussion). J Royal Stat Soc Series B (Methodological) 1973; 35: 189–233

115.

O’Neill R. Early stopping rules workshop: conclusions. Stat Med 1994; 13: 1493–1494

CrossRef116.

Senn S. Statistical issues in drug development. New York (NY): John Wiley & Sons, 2002

117.

van der Wilt GJ, Rovers M, Straatman H, et al. Policy relevance of Bayesian statistics overestimated? Intern J Technol Assess Health Care 2004; 20: 488–492

118.

Richardson S, Leblond L. Some comments on misspecification of priors in Bayesian modeling of measurement error problems. Stat Med 1997; 16: 203–213

PubMedCrossRef119.

Wald A. Statistical decision functions. New York (NY): Wiley, 1950

120.

Ho CH. Some frequentist properties of a Bayesian method in clinical trials. Biom J 1991; 33: 735–740

CrossRef121.

Griffiths WE. Bayesian econometrics and how to get rid of those wrong signs. Rev Market Agricult Econ 1988; 56: 36–56

122.

Sheingold SH. Can Bayesian methods make data and analyses more relevant to decision makers? Internat J Tech Assess Health Care 2001; 17: 114–122

CrossRef123.

Lindley DV. Is our view of Bayesian statistics too narrow? (with discussion). Bayesian Stat 1992; 4: 1–15

124.

Greenland S. Response: Bayesian perspectives for epidemiological research [comment]. Int J Epidemiol 2006; 35: 777–778

CrossRef125.

Greenland S. Bayesian perspectives for epidemiological research: I. Foundations and basic methods. Int J Epidemiol 2006; 35: 765–775

PubMedCrossRef